Examination of PD-1/PD-L1 inhibitor use and adverse events in a real-world setting.

被引：0
|
作者：
Irwin, Debra E.
Brady, Brenna L.
机构：
[1] IBM Watson Hlth, Ann Arbor, MI USA
[2] IBM Watson Hlth, Bethesda, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19294
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ocular adverse events in PD-1 and PD-L1 inhibitors
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen X.
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [2] PD-1/PD-L1 Inhibitor- Related Adverse Events and Their Management in Breast Cancer
    Lei, Chuqi
    Kong, Xiangyi
    Li, Yuan
    Yang, Huaiyu
    Zhang, Ke
    Wang, Zhongzhao
    Chang, Hu
    Xuan, Lixue
    [J]. JOURNAL OF CANCER, 2024, 15 (09): : 2770 - 2787
  • [3] First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between PD-1 and PD-L1 inhibitors in a real-world setting.
    Wang, Dahai
    Gao, Qin Ai
    Sun, Yuping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Immune-Related Adverse Events and their Association with Effectiveness of PD-1/PD-L1 Inhibitors in NSCLC: A Real-World Study from China
    Chen, X.
    Fang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S303 - S303
  • [5] PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)
    Wang, Qiaoyun
    Xiao, Fengjiao
    Zeng, Yanbin
    Zhu, Qiaoling
    Zhang, Haixia
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 257 - 267
  • [6] PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
    Huang, Guili
    Liu, Songqing
    Dong, Jie
    Xi, Xin
    Kong, Rui
    Li, Wenjun
    Du, Qian
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
    Sabate Gallego, Monica
    Perez Esquirol, Eulalia
    Garcia Dolade, Nuria
    Vidal Guitart, Xavier
    Carreras Soler, Maria-Josep
    Farriols Danes, Anna
    Felip, Enriqueta
    Brana, Irene
    Carles Galceran, Joan
    Morales Barrera, Rafael
    Munoz-Couselo, Eva
    Escasany, Antonia Agusti
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [8] Predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data
    So, WeiQing Venus
    Dejardin, David
    Rossmann, Eva
    Charo, Jehad
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [9] Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
    So, WeiQing Venus
    Dejardin, David
    Rossmann, Eva
    Charo, Jehad
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [10] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
    Zhou, Yanting
    Li, Hongyan
    [J]. FRONTIERS IN NEUROSCIENCE, 2023, 17
12345